[{"id":"4b6f2c6e-35f3-4b56-9b34-2f31c986974d","acronym":"BNT111-01","url":"https://clinicaltrials.gov/study/NCT04526899","created_at":"2021-01-18T21:40:45.863Z","updated_at":"2025-02-25T15:26:32.109Z","phase":"Phase 2","brief_title":"Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma","source_id_and_acronym":"NCT04526899 - BNT111-01","lead_sponsor":"BioNTech SE","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • BNT111"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 05/19/2021","start_date":" 05/19/2021","primary_txt":" Primary completion: 01/25/2024","primary_completion_date":" 01/25/2024","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-10"},{"id":"0648059d-a94a-4543-9c17-30dd3ccc0c5a","acronym":"Lipo-MERIT","url":"https://clinicaltrials.gov/study/NCT02410733","created_at":"2021-01-18T11:30:56.690Z","updated_at":"2025-02-25T16:24:31.238Z","phase":"Phase 1","brief_title":"Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma","source_id_and_acronym":"NCT02410733 - Lipo-MERIT","lead_sponsor":"BioNTech SE","biomarkers":" CTAG1B","pipe":"","alterations":" ","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BNT111"],"overall_status":"Completed","enrollment":" Enrollment 119","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 06/20/2023","primary_completion_date":" 06/20/2023","study_txt":" Completion: 06/20/2023","study_completion_date":" 06/20/2023","last_update_posted":"2023-07-19"},{"id":"f1481312-1af8-48f0-b565-97281c722271","acronym":"","url":"https://clinicaltrials.gov/study/NCT04906031","created_at":"2021-05-28T13:52:32.335Z","updated_at":"2024-07-02T16:36:29.356Z","phase":"Phase 2","brief_title":"Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations","source_id_and_acronym":"NCT04906031","lead_sponsor":"First Affiliated Hospital of Jinan University","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • TP53 K139N • TP53 R196* • TP53 R213","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 K139N • TP53 R196* • TP53 R213"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenocta (sodium stibogluconate)"],"overall_status":"Recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2021-06-09"},{"id":"0efd0c25-4f85-4b9c-90a2-c13131a34a18","acronym":"","url":"https://clinicaltrials.gov/study/NCT00629200","created_at":"2021-01-18T02:20:21.030Z","updated_at":"2024-07-02T16:37:05.321Z","phase":"Phase 1","brief_title":"Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies","source_id_and_acronym":"NCT00629200","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IFNA1","pipe":"","alterations":" ","tags":["IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b) • Lenocta (sodium stibogluconate)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 09/13/2006","start_date":" 09/13/2006","primary_txt":" Primary completion: 02/10/2010","primary_completion_date":" 02/10/2010","study_txt":" Completion: 02/10/2010","study_completion_date":" 02/10/2010","last_update_posted":"2018-11-15"}]